Keytruda trials on ice after deaths

The FDA has put on hold three clinical trials involving the immunotherapy pembrolizumab (Keytruda) in combination with other therapies for multiple myeloma, following patient deaths. The US Food and Drug Administration placed two phase III trials on ‘clinical hold’, and a third trial on ‘partial clinical hold’, with the move coming after a data monitoring ...

Already a member?

Login to keep reading.

© 2021 the limbic